A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease
- Bertram, Kelly (Primary Chief Investigator (PCI))
- Burn, Katherine, (Project Manager)
Project: Research